Medtronic, a healthcare technology company based in Ireland, plans to separate its diabetes business into a standalone, publicly traded company by the end of 2026.
The company announced the move May 21, noting the new entity will be a direct-to-consumer business and “the only company to commercialize a complete intensive insulin management ecosystem,” according to a news release.
The diabetes unit employs more than 8,000 people worldwide and represented 8% of Medtronic’s fiscal year 2025 revenue.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
